Key result
Current ibopamine use in chronic heart failure was associated with excess mortality (relative risk 2.03 in NYHA I-II and 1.37 in NYHA III-IV), while specific renal benefits in critical care are lacking.
Why the study?
Does dopamine or dopaminergic treatment improve clinical outcomes or renal function in patients with heart failure and critical illness?
Does dopamine or dopaminergic treatment improve clinical outcomes or renal function in patients with heart failure and critical illness?
Relative Risk: 2.03
The review highlights the lack of evidence for renal benefits of dopamine in critical care and points to unexpected adverse outcomes, including excess mortality, with dopaminergic treatment in chronic heart failure.
No takes yet. Share an insight, caveat, or question.
May increase mortality risk with ibopamine in chronic HF; leaves open any renal role for dopaminergic agents in critical care.
Andries J. Smit (2000) conducted a review in Chronic heart failure and critical care. Dopamine and Ibopamine was evaluated on Mortality (RR 2.03). Current ibopamine use in chronic heart failure was associated with excess mortality (relative risk 2.03 in NYHA I-II and 1.37 in NYHA III-IV), while specific renal benefits in critical care are lacking.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: